News 9 Oct 2026 DNDi 2026 Projects of the Year recognize teams and partners for their work to advance an open-science antiviral for future coronavirus pandemics and a single-dose treatment for sleeping sickness
Scientific articles 9 Oct 2026 A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease ACS Infectious Diseases
Press releases 6 Oct 2026 Ghana’s KNUST and DNDi partner to accelerate drug discovery for neglected diseases in Africa
Scientific articles 5 Oct 2026 Winning the endgame against sleeping sickness: Efficacy profiling of acoziborole against African trypanosomes with the focus on Trypanosoma brucei rhodesiense PLoS Neglected Tropical Diseases
Statements 25 Sep 2026 DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly
In the media 24 Sep 2026 De Etiopía a Lleida: la desigualdad mata tanto como los virus durante una pandemia El País
Scientific articles 22 Sep 2026 Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial The Lancet Infection Diseases
Scientific articles 19 Sep 2026 Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial BMC Medicine
News 15 Sep 2026 New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D
In the media 9 Sep 2026 Des acteurs pharmaceutiques à but non lucratif s’allient pour faire face à la baisse des financements Swissinfo
Scientific articles 1 Sep 2026 Analysis of the therapeutic gap for Trypanosoma cruzi infection inColombia (2012 – 2022) Memórias do Instituto Oswaldo Cruz
Publications 29 Sep 2022 The Science Explained: Evaluating an alternative treatment regimen for visceral leishmaniasis in Eastern Africa
Publications 23 Jun 2022 The Opportunity to Eliminate Hepatitis C through Alternative Financing Mechanisms
Publications 20 Jun 2022 Countermeasure R&D: Global norms for financing risk reduction, resilience & equity
Publications 8 Jun 2022 The Science Explained: Evaluating new treatment regimens for visceral leishmaniasis in people living with HIV in India and Ethiopia
